glp-1 agonists marketing strategies 2025 Market Exclusive Research Report GLP-1 Market Size, Share |

Statements Author contributions All the authors contributed equally to the writing, revision, and editing of this manuscript

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study

This imbalance did not affect the primary endpoint and the incidence rate was higher in patients with a previous history of heart failure and independent of renal function at study baseline (57, 66, 67)

Studies show that retained gastric contents do not correlate with increased aspiration risk, challenging earlier conservative approaches

In the pancreas, this binding stimulates glucose-dependent insulin secretion from beta cells while suppressing inappropriate glucagon release from alpha cells

lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diabetes Care, and Sanofi